Investor Presentaiton
ORION
Key clinical development pipeline
Project/compound
ARANOTE / darolutamide 1
ARASTEP / darolutamide 1
OMAHA1 / ODM-208 (MK-5684-003) 2
OMAHA2a/ ODM-208 (MK-5684-004) 2
Indication
Prostate cancer (mHSPC)
Prostate cancer (BCR)
Prostate cancer (mCRPC)
Prostate cancer (mCRPC)
PHASE I
PHASE II
PHASE III REGISTRATION
Ongoing
Ongoing
Initiated
Initiated
CYPIDES/ODM-208 2
Prostate cancer (mCRPC)
Ongoing
Phase lla
ODM-105/tasipimidine
Insomnia
Ongoing
ODM-111 (NaV 1.8 blocker)
Pain
Ongoing
ODM-212 (TEAD inhibitor)
Solid tumours
Ongoing
Oncology
Pain / neurology
In collaboration with Bayer
2 In collaboration with MSD
10
Investor Presentation Orion Corporation
Changes vs. Q3'2023:
OMAHA1 / ODM-208 (MK-5684-003) phase III initiated
OMAHA2a / ODM-208 (MK-5684-004) phase III initiatedView entire presentation